United Therapeutics Corp., of Silver Spring, a biotechnology company that develops products to address chronic and life-threatening conditions, reported increases in profit and revenue for the quarter ended June 30. Net income was $111.9 million, or $2.35 per share, compared with $79.9 million and $1.60 for the same quarter in 2013. Revenue totaled $322.8 million, increased from $280.6 million in the prior-year period. United Therapeutics’ cardiopulmonary products all showed increased sales during the quarter, and the company launched Orenitram during the period, which generated $6.6 million in revenue. Orenitram is a vasodilator — which widens blood vessels — designed to enable those with hypertension to improve exercise capacity.